In Brief
- Ajay Devgn challenges FDA notice over Vimal Elaichi advertisements.
- Petition argues notice wrongly targets actor, not manufacturing company.
- Case filed in Maharashtra High Court by Devgn's legal team.
- Dispute highlights regulatory action focus on advertisement endorsers.
Actor Ajay Devgn moves Maharashtra High Court against FDA notice
Noted Bollywood actor Ajay Devgn has approached the Maharashtra High Court, contesting a notice issued by the Food and Drug Administration (FDA) concerning advertisements for Vimal Elaichi. The petitioner argues that the notice was arbitrarily directed at him as the endorser, rather than at the manufacturing company responsible for the product.
According to the petition, the notice implicates Devgan personally for the advertisement content, which the actor’s legal representatives contend is inappropriate and unwarranted. The actor asserts that liability should lie with the product's manufacturer instead of the brand ambassador.
The matter has drawn attention to the regulatory scope and accountability within advertising, especially with celebrity endorsements of consumer products. While the FDA enforces compliance with advertising guidelines, the question of whether endorsers should face notices has sparked discussion.
Though official FDA statements on this case remain limited, the High Court will now examine the validity of the notice and the grounds for issuing it to Ajay Devgan. The case is expected to set a precedent regarding the responsibilities and protections for celebrities endorsing products under regulatory scrutiny.
